文献速递心境障碍物质与行为成瘾儿童青少年精神

精神病理学脑源性维度框架研究

Framework for Brain-Derived Dimensions of Psychopathology.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该诊断性研究基于IMAGEN人群队列与STRATIFY/ESTRA跨诊断样本,用稀疏广义典型相关分析整合临床症状与7种脑影像模态,将ICD-10与DSM-5症状重组为6个跨诊断精神病理学评分,并与多模态神经影像成分稳定关联。

要点

  • ICD-10与DSM-5症状可重组为6个跨诊断精神病理学评分。
  • 6个评分均与多模态神经影像成分在训练集、测试集及独立样本中一致关联。
  • 该框架为基于可量化神经生物学指标刻画精神病理维度提供依据。

核心结论

  • 现有精神科诊断未由神经生物学指标定义,阻碍针对精神疾病机制的疗法开发。
  • 将ICD-10与DSM-5症状按共变与共享脑机制重组,可识别由脑机制稳健定义的症状群。

研究设计与样本

  • 诊断性研究,使用IMAGEN人群队列(14、19、23岁纵向评估)与STRATIFY/ESTRA跨诊断样本。
  • 样本来自德国、英国、法国、爱尔兰8家临床研究医院;IMAGEN中1253名23岁参与者有794人完成全部评估,STRATIFY/ESTRA中485名18至26岁参与者有209人数据完整。
  • 样本含健康对照及酒精使用障碍、重性抑郁障碍、神经性厌食症、神经性贪食症患者,采用稀疏广义典型相关分析整合临床症状与7种脑影像模态。
  • 模型在IMAGEN 23岁训练集(70%)开发,应用于剩余30%保留测试集、独立STRATIFY/ESTRA样本及IMAGEN纵向数据。

主要发现

  • 共纳入1003名参与者(425男、578女;平均[SD]年龄22.1[1.5]岁)。
  • 重组现有ICD-10与DSM-5症状后得到6个跨诊断精神病理学评分。
  • 兴奋性与冲动性评分与神经影像成分关联:训练集r=0.26(95%CI 0.18-0.33),测试集r=0.22(95%CI 0.10-0.35),STRATIFY/ESTRA集r=0.19(95%CI 0.07-0.31)。
  • 抑郁心境与痛苦评分:训练集r=0.30(95%CI 0.20-0.38),测试集r=0.22(95%CI 0.09-0.35),STRATIFY/ESTRA集r=0.19(95%CI 0.04-0.33)。
  • 情绪与行为失调评分:训练集r=0.40(95%CI 0.31-0.48),测试集r=0.17(95%CI 0.14-0.36),STRATIFY/ESTRA集r=0.19(95%CI 0.06-0.30)。

关键数值与推荐

  • 应激病理评分:训练集r=0.32(95%CI 0.19-0.43),测试集r=0.14(95%CI 0.05-0.23),STRATIFY/ESTRA集r=0.12(95%CI 0.01-0.22)。
  • 进食病理评分:训练集r=0.34(95%CI 0.25-0.42),测试集r=0.26(95%CI 0.15-0.37),STRATIFY/ESTRA集r=0.15(95%CI 0.12-0.34)。
  • 社交恐惧与回避评分:训练集r=0.31(95%CI 0.25-0.42),测试集r=0.18(95%CI 0.15-0.35),STRATIFY/ESTRA集r=0.12(95%CI 0.12-0.33)。

临床怎么用

  • 提示临床可按6个跨诊断维度而非仅按诊断边界评估症状与脑机制。
  • 症状评分与多模态神经影像成分的关联可支持基于可量化神经生物学指标刻画精神病理维度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psychiatric diagnoses are not defined by neurobiological measures hindering the development of therapies targeting mechanisms underlying mental illness. Research confined to diagnostic boundaries yields heterogeneous biological results, whereas transdiagnostic studies often investigate individual symptoms in isolation. OBJECTIVE: To develop a framework that groups clinical symptoms compatible with ICD-10 and DSM-5 according to their covariation and shared brain mechanisms. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study was conducted in 2 samples, the population-based Reinforcement-Related Behaviour in Normal Brain Function and Psychopathology (IMAGEN) cohort (longitudinal assessments at 14, 19, and 23 years; study duration from March 2010 to the present) and the cross-diagnostic Brain Network Based Stratification of Mental Illness (STRATIFY)/Earlier Detection and Stratification of Eating Disorders and Comorbid Mental Illnesses (ESTRA) samples (study duration from October 2016 to September 2023). The samples are from 8 clinical research hospitals in Germany, the UK, France, and Ireland. For the population-based IMAGEN study, 794 of 1253 23-year-old participants had complete assessments including complete clinical assessments and neuroimaging data across all time points. For the cross-diagnostic STRATIFY/ESTRA samples, 209 of 485 participants aged 18 to 26 years had complete clinical and neuroimaging data. The sample included healthy control individuals and patients with alcohol use disorder, major depressive disorder, anorexia nervosa, and bulimia nervosa. EXPOSURES: Sparse generalized canonical correlation analysis was used to integrate diverse data from clinical symptoms and 7 brain imaging modalities. MAIN OUTCOMES AND MEASURES: The prediction of symptom features was the main outcome. The model was developed in the training set from the IMAGEN Study at age 23 years (70%), then applied in the remaining holdout test sample (30%), the independent STRATIFY/ESTRA patient sample, and longitudinally in the IMAGEN set. RESULTS: In total, 1003 participants were included (425 male and 578 female; mean [SD] age, 22.1 [1.5] years). The reassembly of existing ICD-10 and DSM-5 symptoms revealed 6 cross-diagnostic psychopathology scores. They were consistently associated with multimodal neuroimaging components: excitability and impulsivity (training set: r, 0.26; 95% CI, 0.18-0.33; test set: r, 0.22; 95% CI, 0.10-0.35; STRATIFY/ESTRA set: r, 0.19; 95% CI, 0.07-0.31), depressive mood and distress (training: r, 0.30; 95% CI, 0.20-0.38; test: r, 0.22; 95% CI, 0.09-0.35; STRATIFY/ESTRA: r, 0.19; 95% CI, 0.04-0.33), emotional and behavioral dysregulation (training: r, 0.40; 95% CI, 0.31-0.48; test: r, 0.17; 95% CI, 0.14-0.36; STRATIFY/ESTRA: r, 0.19; 95% CI, 0.06-0.30), stress pathology (training: r, 0.32; 95% CI, 0.19-0.43; test: r, 0.14; 95% CI, 0.05-0.23; STRATIFY/ESTRA: r, 0.12; 95% CI, 0.01-0.22), eating pathology (training: r, 0.34; 95% CI, 0.25-0.42; test: r, 0.26; 95% CI, 0.15-0.37; STRATIFY/ESTRA: r, 0.15; 95% CI, 0.12-0.34), and social fear and avoidance symptoms (training: r, 0.31; 95% CI, 0.25-0.42; test: r, 0.18; 95% CI, 0.15-0.35; STRATIFY/ESTRA: r, 0.12; 95% CI, 0.12-0.33). CONCLUSION AND RELEVANCE: In this study, the identification of symptom groups of mental illness robustly defined by precisely characterized brain mechanisms enabled the characterization of dimensions of psychopathology based on quantifiable neurobiological measures.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lett TA, Vaidya N, Jia T, et al. Framework for Brain-Derived Dimensions of Psychopathology. JAMA Psychiatry. 2025. PMID: 40531512. doi:10.1001/jamapsychiatry.2025.1246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。